ESR1 ligand binding domain mutations in hormone-resistant breast cancer

ESR1 ligand binding domain mutations in hormone-resistant breast cancer

Seventy percent of breast cancers express estrogen receptor (ER) and most of these are sensitive to ER inhibition. However, many such tumors become refractory to inhibition of estrogen action in the metastatic setting for unknown reasons. We conducted a comprehensive genetic analysis of two independ...

Full description

Bibliographic Details
Main Authors: Toy, Weiyi, Shen, Yang, Won, Helen, Green, Bradley, Sakr, Rita A., Will, Marie, Li, Zhiqiang, Gala, Kinisha, Fanning, Sean, King, Tari A., Hudis, Clifford, Chen, David, Taran, Tetiana, Hortobagyi, Gabriel, Greene, Geoffrey, Berger, Michael, Baselga, Jose, Chandarlapaty, Sarat
Format: Online
Language:English
Published: 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903423/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903423/

Similar Items